Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00405574 | Study of ATN-224 in Patients With Prostate Cancer | unknown | Phase 2 | 50 | AttenuonINDUSTRY | 1 | Jan 30, 2008 | clinicaltrials |
| NCT00072930 | MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer | completed | Phase 2 | 150 | MedImmune LLCINDUSTRY | 7 | Jan 15, 2008 | clinicaltrials |
| NCT00140348 |
| Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine |
| completed |
| Phase 1 / Phase 2 |
| 80 |
| Cell GenesysINDUSTRY |
| 1 |
| Dec 24, 2007 |
| clinicaltrials |
| NCT00121095 | Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer | unknown | Phase 1 / Phase 2 | 69 | Cytogen CorporationINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00138138 | Psychostimulants for Fatigue in Prostate Cancer | completed | Phase 2 | 120 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2007 | clinicaltrials |
| NCT00127478 | A Long Term Safety Study With Atrasentan | completed | Phase 2 / Phase 3 | 166 | AbbottINDUSTRY | 5 | Nov 29, 2007 | clinicaltrials |
| NCT00245895 | Study of Aranesp to Treat Anemia in Prostate Cancer Patients. | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Nov 29, 2007 | clinicaltrials |
| NCT00283829 | Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 30 | University of WashingtonOTHER | 1 | Nov 29, 2007 | clinicaltrials |
| NCT00418080 | Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy | completed | Phase 2 | 86 | University of L'AquilaOTHER | 1 | Oct 8, 2007 | clinicaltrials |
| NCT00421694 | Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide | completed | Phase 2 / Phase 3 | 119 | University of L'AquilaOTHER | 1 | Oct 8, 2007 | clinicaltrials |
| NCT00115635 | Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 60 | Herlev HospitalOTHER | 1 | Oct 2, 2007 | clinicaltrials |
| NCT00070837 | MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 46 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 13, 2007 | clinicaltrials |
| NCT00200187 | A Randomized Study of the Efficacy of Low Venous Pressure General Anesthesia Versus Combined Spinal-Epidural Anesthesia in Decreasing Blood Loss During Prostate Surgery | completed | Phase 2 | 246 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00040586 | Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2 | completed | Phase 2 | — | BZL BiologicsINDUSTRY | 1 | Jan 22, 2007 | clinicaltrials |
| NCT00072722 | Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) | completed | Phase 2 | 36 | Celgene CorporationINDUSTRY | 1 | Dec 19, 2006 | clinicaltrials |
| NCT00132756 | Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Morton Plant Mease Health CareOTHER | 1 | Nov 8, 2006 | clinicaltrials |
| NCT00040170 | Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer | terminated | Phase 2 | 50 | TransgeneINDUSTRY | 1 | Nov 2, 2006 | clinicaltrials |
| NCT00100243 | Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy | completed | Phase 2 | 22 | PRAECIS Pharmaceuticals Inc.INDUSTRY | 1 | Sep 19, 2006 | clinicaltrials |
| NCT00127088 | Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients | suspended | Phase 2 | 37 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 11, 2006 | clinicaltrials |
| NCT00039793 | Massage Therapy for Cancer-Related Fatigue | completed | Phase 2 | 45 | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
| NCT00038662 | Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure | completed | Phase 2 | 200 | AbbottINDUSTRY | 2 | Aug 15, 2006 | clinicaltrials |
| NCT00188383 | Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy | unknown | Phase 1 / Phase 2 | 132 | University Health Network, TorontoOTHER | 1 | Mar 14, 2006 | clinicaltrials |
| NCT00103428 | Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 69 | Cell GenesysINDUSTRY | 1 | Feb 2, 2006 | clinicaltrials |
| NCT00179738 | A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer. | terminated | Phase 2 | 40 | Celgene CorporationINDUSTRY | 1 | Nov 23, 2005 | clinicaltrials |
| NCT00215345 | A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer | unknown | Phase 2 | 66 | Department of Veterans Affairs, New JerseyFED | 1 | Sep 22, 2005 | clinicaltrials |
| NCT00218205 | A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer | unknown | Phase 2 | 28 | Department of Veterans Affairs, New JerseyFED | 1 | Sep 22, 2005 | clinicaltrials |
| NCT00164437 | CD-ROM Intervention for Prostate Cancer Screening | completed | Phase 2 / Phase 3 | 554 | Centers for Disease Control and PreventionFED | 1 | Sep 14, 2005 | clinicaltrials |
| NCT00140374 | Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer) | completed | Phase 1 / Phase 2 | 36 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140387 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) | completed | Phase 1 / Phase 2 | 20 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140400 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 50 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00116155 | Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | — | Cell GenesysINDUSTRY | 0 | Jun 28, 2005 | clinicaltrials |
| NCT00061126 | ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body | completed | Phase 2 | 50 | AbgenixINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jan 30, 2008source: clinicaltrials